Christopher M Pieczonka
Overview
Explore the profile of Christopher M Pieczonka including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
380
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Freedland S, Gleave M, De Giorgi U, Rannikko A, Pieczonka C, Tutrone Jr R, et al.
Future Oncol
. 2024 Dec;
21(5):501-514.
PMID: 39667819
No abstract available.
2.
Freedland S, Gleave M, De Giorgi U, Rannikko A, Pieczonka C, Tutrone R, et al.
NEJM Evid
. 2024 Feb;
2(12):EVIDoa2300251.
PMID: 38320501
BACKGROUND: EMBARK, a controlled trial reported elsewhere, showed enzalutamide plus leuprolide (combination) and enzalutamide monotherapy prolonged metastasis-free survival versus placebo plus leuprolide (alone) in patients with high-risk biochemically recurrent prostate...
3.
Shen J, Chowdhury S, Agarwal N, Karsh L, Oudard S, Gartrell B, et al.
Br J Cancer
. 2023 Nov;
130(1):73-81.
PMID: 37951974
Background: Apalutamide plus androgen-deprivation therapy (ADT) improved outcomes in metastatic castration-sensitive prostate cancer (mCSPC) and non-metastatic castration-resistant PC (nmCRPC) in the Phase 3 randomised TITAN and SPARTAN studies, respectively, and...
4.
Freedland S, de Almeida Luz M, De Giorgi U, Gleave M, Gotto G, Pieczonka C, et al.
N Engl J Med
. 2023 Oct;
389(16):1453-1465.
PMID: 37851874
Background: Patients with prostate cancer who have high-risk biochemical recurrence have an increased risk of progression. The efficacy and safety of enzalutamide plus androgen-deprivation therapy and enzalutamide monotherapy, as compared...
5.
Shore N, Polikarpov D, Pieczonka C, Henderson R, Bailen J, Saltzstein D, et al.
Urol Oncol
. 2023 Sep;
41(11):454.e9-454.e16.
PMID: 37734979
Background: There is a clinical need to identify patients with an elevated PSA who would benefit from prostate biopsy due to the presence of clinically significant prostate cancer (CSCaP). We...
6.
Pieczonka C, Mariados N, Sylvester J, Karsh L, Hudes R, Beyer D, et al.
Urol Pract
. 2023 Aug;
3(2):141-146.
PMID: 37592484
Introduction: We evaluate the safety, tolerability and impact on therapy of an absorbable hydrogel perirectal spacer (SpaceOAR® system) designed to reduce the rectal radiation dose during prostate cancer radiotherapy. Methods:...
7.
Antonarakis E, Subudhi S, Pieczonka C, Karsh L, Quinn D, Hafron J, et al.
Clin Cancer Res
. 2023 Apr;
29(13):2426-2434.
PMID: 37058234
Purpose: We present long-term outcomes from 2 randomized studies [STAMP (with abiraterone, NCT01487863) and STRIDE (with enzalutamide, NCT01981122)] that were performed to study the impact of sequential or concurrent administration...
8.
Shore N, Pieczonka C, Henderson R, Bailen J, Saltzstein D, Concepcion R, et al.
Urol Oncol
. 2020 May;
38(8):683.e1-683.e10.
PMID: 32360170
Background: Increasing numbers of patients are presenting with aggressive prostate cancer (CaP); therefore, there exists a need to optimally identify these patients pre-biopsy. Objectives: To compare the accuracy of total...
9.
Shore N, Pieczonka C, Henderson R, Bailen J, Saltzstein D, Concepcion R, et al.
Urol Oncol
. 2020 Apr;
38(8):683.e11-683.e18.
PMID: 32305266
Background: A clinical need exists for a biomarker test to accurately delineate aggressive prostate cancer (AgCaP), and thus better assist clinicians and patients decision-making on whether to proceed to prostate...
10.
Higano C, Armstrong A, Sartor O, Vogelzang N, Kantoff P, McLeod D, et al.
Cancer
. 2020 Mar;
126(12):2935-2937.
PMID: 32154908
No abstract available.